U.S. markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
808.31-9.72 (-1.19%)
At close: 04:00PM EDT
808.40 +0.09 (+0.01%)
After hours: 07:09PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close818.03
Bid791.62 x 800
Ask825.00 x 800
Day's Range799.77 - 813.28
52 Week Range668.00 - 847.50
Avg. Volume524,150
Market Cap87.749B
Beta (5Y Monthly)0.19
PE Ratio (TTM)21.68
EPS (TTM)37.29
Earnings DateNov 02, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est907.48
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
-1% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for REGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regeneron Pharmaceuticals, Inc.
    Analyst Report: Regeneron Phars, IncRegeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 11,850 employees worldwide, and is based in Tarrytown, New York.
    Fair Value
    Economic Moat
    19 days agoArgus Research
View more
  • GlobeNewswire

    Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

    Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collabo

  • Simply Wall St.

    Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Motley Fool

    Stock Split Watch: Is Regeneron Pharmaceuticals Next?

    Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's holdings, but it does bring down the price of each individual share. Of course, it's impossible to predict which company may perform a stock split with 100% accuracy, but a top performer that has been setting new share price highs could make a good candidate.